TriSalus Life Sciences, Inc. (TLSI)

9.85 +0.15 (+1.55%) At close: 04:00PM EDT

TriSalus Life Sciences, Inc.

6272 West 91st Avenue
Westminster, CO 80031
United States
303 442 1222
https://trisaluslifesci.com

Sector(s): Healthcare
Industry: Medical Devices
Full-time employees: 112

Key executives

Name	Title	Pay	Exercised	Year born
Ms. Mary T. Szela B.S.N., M.B.A.	CEO, President & Director	880.67k	N/A	1964
Mr. Sean Edward Murphy	CFO & Director	628.75k	N/A	1953
Dr. Steven C. Katz F.A.C.S., M.D.	Chief Medical Officer & Chairman of Scientific Advisory Board	849.89k	N/A	1975
Ms. Lori Ann Santamaria	Vice President of Operations	N/A	N/A	N/A
Dr. Bryan F. Cox Ph.D.	Chief Scientific & Manufacturing Officer	N/A	N/A	1962
Mr. James E. Young	Senior VP of Investor Relations & Treasurer	N/A	N/A	N/A
Ms. Rachel Garcia	Marketing Manager	N/A	N/A	N/A
Dr. Richard B. Marshak M.B.A., MBA, VMD	Senior Vice President of Corporate Development & Strategy	N/A	N/A	1959
Ms. Jennifer L. Stevens J.D.	Chief Regulatory Officer	630k	N/A	1961
Ms. Jodi Devlin	President of Commercial Operations	N/A	N/A	1962

Amounts are as of 31 December 2023, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

TriSalus Life Sciences, Inc., a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer. It also develops nelitolimod, an investigational immunotherapeutic in Phase 1 clinical trial for the treatment of uveal melanoma with liver metastases, hepatocellular carcinoma, intrahepatic cholangiocarcinoma, and locally advanced pancreatic ductal adenocarcinoma. The company serves interventional radiologists, IR technicians, medical oncologists, nursing support, value analysis committee staff, and patients through its sales representatives and sales managers. TriSalus Life Sciences, Inc. was founded in 2009 and is headquartered in Westminster, Colorado.

Corporate governance

TriSalus Life Sciences, Inc.’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.